The brokerag highlighted that Indegene is the only listed, pure-play life sciences commercialisation company at scale, with global rivals like EVERSANA and Syneos, and its 18%+ earnings growth comfortably supporting a valuation toward the lower-middle end of Indian IT-services peer range.
The brokerag highlighted that Indegene is the only listed, pure-play life sciences commercialisation company at scale, with global rivals like EVERSANA and Syneos, and its 18%+ earnings growth comfortably supporting a valuation toward the lower-middle end of Indian IT-services peer range.
<iframe src="https://hindustansphere.com/embed/cluster/980cb2e5de99b930aa8fdc3c87acd2158236ab95" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Indegene Shares In Focus As IDBI Capital Initiates Coverage — Check Target Price, Upside And More"></iframe>
